HC Wainwright & Co. Maintains Buy on Ocuphire Pharma, Lowers Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Matthew Caufield maintains a Buy rating on Ocuphire Pharma (NASDAQ:OCUP) but lowers the price target from $20 to $18.
August 15, 2024 | 10:03 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. maintains a Buy rating on Ocuphire Pharma but lowers the price target from $20 to $18.
The Buy rating suggests continued confidence in Ocuphire Pharma's prospects, but the lowered price target indicates some tempered expectations. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100